Cai Run, Ren Jianke, Zhou Chenwei, Liu Yuxin, Tang Jianlei, Cui Weiyan, Yan Yongmin, Xue Sheliang, Zhou Yanjuan
Department of Respiratory and Critical Care Medicine, Wujin Hospital Affiliated with Jiangsu University, Changzhou, China.
National Health Commission Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China.
Acta Biochim Pol. 2025 Mar 19;72:13958. doi: 10.3389/abp.2025.13958. eCollection 2025.
This study aimed to evaluate the potential of interleukin-34 (IL-34) as a novel biomarker for predicting mortality in sepsis patients, with a specific focus on those with sepsis-induced acute lung injury (ALI).
This prospective cohort study enrolled 115 sepsis patients admitted to the intensive care unit (ICU). The patients were divided into survival and non-survival groups, as well as ALI and non-ALI subgroups. Serum levels of IL-34, in conjunction with other established biomarkers such as interleukin-6 (IL-6), C-reactive protein (CRP), and lactate, were measured and analyzed. Statistical analyses, including receiver operating characteristic (ROC) curves, Kaplan-Meier survival curves and Cox regression models, were used to determine the prognostic significance of IL-34.
Serum IL-34 levels were significantly elevated in sepsis patients compared to healthy controls, and they were also higher in non-survival group compared to survival group ( < 0.05). Additionally, IL-34 levels exhibited a positive correlation with sepsis severity, as indicated by APACHE II and SOFA scores. Kaplan-Meier survival curves and multivariate COX regression analysis revealed that IL-34 is an independent risk factor for death within 28 days of sepsis. The serum IL-34 level in the ALI group was significantly higher than that in the non-ALI group, particularly in severe cases ( < 0.05). However, the prognostic value of IL-34 in sepsis-induced ALI requires further investigation.
IL-34 shows promise as an independent prognostic factor in sepsis patients and may enhance risk stratification, especially in those with sepsis-induced ALI.
本研究旨在评估白细胞介素-34（IL-34）作为预测脓毒症患者死亡率的新型生物标志物的潜力，特别关注脓毒症诱导的急性肺损伤（ALI）患者。
这项前瞻性队列研究纳入了115名入住重症监护病房（ICU）的脓毒症患者。患者被分为存活组和非存活组，以及ALI和非ALI亚组。测量并分析了IL-34的血清水平，以及其他已确立的生物标志物，如白细胞介素-6（IL-6）、C反应蛋白（CRP）和乳酸。使用包括受试者工作特征（ROC）曲线、Kaplan-Meier生存曲线和Cox回归模型在内的统计分析来确定IL-34的预后意义。
与健康对照组相比，脓毒症患者的血清IL-34水平显著升高，与存活组相比，非存活组的IL-34水平也更高（<0.05）。此外，IL-34水平与脓毒症严重程度呈正相关，如APACHE II和SOFA评分所示。Kaplan-Meier生存曲线和多变量COX回归分析显示，IL-34是脓毒症28天内死亡的独立危险因素。ALI组的血清IL-34水平显著高于非ALI组，尤其是在严重病例中（<0.05）。然而，IL-34在脓毒症诱导的ALI中的预后价值需要进一步研究。
IL-34有望作为脓毒症患者的独立预后因素，并可能增强风险分层，特别是在脓毒症诱导的ALI患者中。
